News

These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.

The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a breakdown of the latest news in diabetes management, including FDA clearance of a new insulin pump and a major acquisition within the diabetes world.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.

JB Boone, MD, explains the progress being made towards more personalized medicine in patients with rheumatoid arthritis, as well as the current challenges.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

JB Boone, MD, explains PrismRA, a predictive tool designed to determine whether a patient will likely have an inadequate response to a TNF inhibitor.

A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.

Jordan Baeker Bispo, PhD, MPH, discusses the importance of colorectal cancer screening, why clinician screening recommendations are so important, and how patient-clinician communication gaps should be addressed.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

A study reveals a link between low free thyroxine and fatty liver risk in type 2 diabetes patients, suggesting a gender-specific thyroid-liver interaction.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

The association between antibiotic exposure and increased odds of AMD persisted after adjustment for well-established risk factors for the disease.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

Ahmad Masri, MD, MS, provides his perspective on the APOLLO-B data and reacts to the FDA CRDAC 9 to 3 vote in favor of the benefit-risk profile for patisiran in ATTR-CM.

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.

Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.

This new Morbidity and Mortality Weekly Report on the CDC site indicates the importance of influenza vaccination, especially for at-risk populations.

A confirmatory efficacy and safety study demonstrated therapeutic equivalence, immunogenicity, pharmacokinetics, and safety of an aflibercept biosimilar.

These findings highlight the potential of dupilumab treatment in improving lung function among children that are shown to have uncontrolled, moderate-to-severe type 2 asthma.

Rates of visual acuity loss among patients with neovascular age-related macular degeneration did not vary significantly in pre‐versus post‐lockdown time periods.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.

Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.

Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.

HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.

Males in the highest serum uric acid tier were significantly more likely to be diagnosed with peripheral artery disease, although a similar trend was not observed in female patients.